

Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/PFA8ECD9C921EN.html>

Date: January 2022

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: PFA8ECD9C921EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in "Phosphatidylinositol 3 kinase delta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

"Phosphatidylinositol 3 kinase delta inhibitors Understanding

"Phosphatidylinositol 3 kinase delta inhibitors: Overview

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence “Phosphatidylinositol 3 kinase delta inhibitors R&D. The therapies under development are focused on novel approaches for “Phosphatidylinositol 3 kinase delta inhibitors.

“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs Chapters

This segment of the “Phosphatidylinositol 3 kinase delta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs

Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral inhibitor of PI3K-delta and CK1-epsilon administered once daily. Umbralisib is presently being evaluated in patients with Non-Hodgkin's lymphoma (NHL) and Chronic lymphocytic leukaemia (CLL) in combination with other agents including ublituximab. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in many important cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity.

Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K δ). It is currently under evaluation as a monotherapy in several ongoing Phase 2 trials as a treatment for non-Hodgkin lymphomas (follicular, marginal zone and mantle cell); and autoimmune hemolytic anemia. Pivotal trials of parsaclisib in combination with ruxolitinib for the treatment of patients with myelofibrosis are underway; and there are plans to initiate a trial to evaluate parsaclisib in combination with tafasitamab for B-cell malignancies. In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates, including parsaclisib. Under the terms of the agreement, Innovent has received the rights to develop and commercialize parsaclisib

and two other assets in Mainland China, Hong Kong, Macau and Taiwan.

Further product details are provided in the report.....

“Phosphatidylinositol 3 kinase delta inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different “Phosphatidylinositol 3 kinase delta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on “Phosphatidylinositol 3 kinase delta inhibitors

There are approx. 20+ key companies which are developing the “Phosphatidylinositol 3 kinase delta inhibitors. The companies which have their “Phosphatidylinositol 3 kinase delta inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, TG Therapeutics.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

“Phosphatidylinositol 3 kinase delta inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been

categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

“Phosphatidylinositol 3 kinase delta inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses “Phosphatidylinositol 3 kinase delta inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging “Phosphatidylinositol 3 kinase delta inhibitors drugs.

“Phosphatidylinositol 3 kinase delta inhibitors Report Insights

“Phosphatidylinositol 3 kinase delta inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

“Phosphatidylinositol 3 kinase delta inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing “Phosphatidylinositol 3 kinase delta inhibitors drugs?”

How many “Phosphatidylinositol 3 kinase delta inhibitors drugs are developed by each company?”

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of “Phosphatidylinositol 3 kinase delta inhibitors?”

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the “Phosphatidylinositol 3 kinase delta inhibitors therapeutics?”

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?”

What are the clinical studies going on for “Phosphatidylinositol 3 kinase delta inhibitors and their status?”

What are the key designations that have been granted to the emerging drugs?”

Key Players

TG Therapeutics

Incyte Corporation

Nanjing Zenshine Pharmaceuticals

Shanghai Yingli Pharmaceutical

Bayer HealthCare Pharmaceuticals

Novartis

Rhizen Pharmaceuticals

Secura Bio

Applied Therapeutics

Hillstream BioPharma

Celon pharma

Yuhan

Gilead Sciences

Chia Tai Tianqing Pharmaceutical Group

Acerta Pharma

BR 101801

BeiGene

Nanjing Sanhome Pharmaceutical

Hutchison MediPharma

Calistoga Pharmaceuticals

Kyowa Kirin

Key Products

Umbralisib

Parsaclisib

Zandelisib

ZX 101A

Linperlisib

CAL-101

SHC 014748M

HMPL-689

BGB-10188

BR 101801

ACP 319

Copanlisib

TQ B3525

Leniolisib

GS-9820

Tenalisib

YH 25248

Duvelisib

HSB-501

AT-104

Contents

Introduction

Executive Summary

“Phosphatidylinositol 3 kinase delta inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

“Phosphatidylinositol 3 kinase delta inhibitors – DelveInsight’s Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

Umbralisib: TG Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tenalisib: Rhizen Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

ZX 101A: Nanjing Zenshine Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
AT-104: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
“Phosphatidylinositol 3 kinase delta inhibitors Key Products
“Phosphatidylinositol 3 kinase delta inhibitors- Unmet Needs
“Phosphatidylinositol 3 kinase delta inhibitors- Market Drivers and Barriers
“Phosphatidylinositol 3 kinase delta inhibitors- Future Perspectives and Conclusion
“Phosphatidylinositol 3 kinase delta inhibitors Analyst Views
“Phosphatidylinositol 3 kinase delta inhibitors Key Companies
Appendix

I would like to order

Product name: Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PFA8ECD9C921EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFA8ECD9C921EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970